Transforming life for people living with Parkinson’s and other CNS disorders

Transforming life for people living with Parkinson’s and other CNS disorders

LATEST PRESS RELEASES
NOVEMBER 29, 2024

IRLAB to present at ABGSC Investor Days on December 4, 2024

Gothenburg, Sweden, November 29, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will present at the ABGSC Investor Days on Wednesday, December 4, 2024, in Stockholm, Sweden.

Read More >

Watch IRLAB’s
Capital Markets Day 2023!

IRLAB A
12.45
SEK
TODAY
-0.80 %
TODAY SEK
-0.10 SEK
17:00:00
2024-12-05
More share info >

ISP – The proprietary technology platform

IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.

IRLAB’s clinical phase II candidates

Mesdopetam (IRL790)

In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.  

Pirepemat (IRL752)

In development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease.

LATEST PRESENTATION
OCTOBER 25, 2024

Presentation at Redeye’s Theme Event Neurology

Presentation by Kristina Torfgård, CEO, at “Theme Event Neurology”, an event hosted by Redeye, held on October 23, 2024.

Read More >